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OBJECTIVES The goal of this study was to use serial (postirradiation and follow-up) volumetric
intravascular ultrasound (IVUS): 1) to evaluate the actual distribution of gamma radiation in
human in-stent restenosis (ISR) lesions, and 2) to analyze the relationship between
neointimal regrowth and the delivered radiation dose.
BACKGROUND The relationship between the neointimal regrowth and delivered dose during the treatment
of ISR remains unknown.
METHODS We analyzed 20 actively (gamma emitter) treated, native artery ISR patients from the
Washington Radiation for In-Stent restenosis Trial (WRIST) that met the following criteria:
on both postirradiation and six-month follow-up IVUS imaging,80% of the external elastic
membrane circumference could be identified throughout the treated length including the
lesion and proximal and distal reference segments. Intravascular ultrasound images were
digitized every 1 mm. Proximal and distal reference and stented segment luminal and
adventitial contours were imported and reconstructed. The source was placed circumferen-
tially at the site of the IVUS catheter and longitudinally according to the relationship between
the radioactive seeds and stent edges. Using Monte Carlo simulations, dose volume
histograms for the adventitia and intima were calculated. The relationship between the
neointimal regrowth and calculated doses were evaluated.
RESULTS There was large dose heterogeneity at both the intimal and adventitial levels. Most of the sites
(93%) received 4 Gy at the adventitia, and all of the sites received 4 Gy at the intima.
There was no relationship between neointimal regrowth and radiation dose.
CONCLUSIONS Although there may be large dose heterogeneity, gamma irradiation (using a fixed dose
prescription) appears to deliver a sufficient dose to prevent neointimal regrowth. (J Am Coll
Cardiol 2002;39:1937–42) © 2002 by the American College of Cardiology Foundation
Intravascular brachytherapy has been evaluated in a number
of clinical settings including de novo lesions, restenotic
lesions, newly stented lesions and in-stent restenosis (ISR)
lesions in both native arteries and saphenous vein grafts
(1–3). As a result of randomized, placebo controlled clinical
trials, the Food and Drug Administration has approved
brachytherapy for the treatment of ISR. The purpose of the
current study was to use serial (postirradiation and follow-
up) volumetric intravascular ultrasound (IVUS) analysis: 1)
to evaluate the actual distribution of gamma radiation to the
intima and adventitia in native artery ISR lesions, and 2) to
analyze the relationship between the neointimal regrowth
and the calculated dose.
METHODS
Patient population. We analyzed 20 actively treated, na-
tive artery ISR patients from Washington Radiation for
In-Stent restenosis Trial (WRIST), a randomized, placebo-
controlled trial of gamma-irradiation for the treatment of
ISR. The WRIST study enrolled 50 patients with native
artery ISR. Thirty-six of these patients had postirradiation
and follow-up IVUS imaging. The 20 patients in the
current analysis were selected because 80% of the external
elastic membrane (EEM) circumference could be identified
throughout the treated length (including the lesion and
proximal and distal reference segments) on both postirradi-
ation and six-month follow-up IVUS imaging and because
they were treated with the same dose prescription.
Radiation procedure. The details of the radiation proce-
dure have been reported previously (3). A closed end-lumen
5.0F noncentered catheter (Medtronic Vascular Interven-
tional, Minneapolis, Minnesota) was inserted into the vessel
and positioned at the ISR lesion. The radiation source—
192Ir (Best Medical International, Beuningen, The Nether-
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lands)—was hand-loaded into the closed end-lumen cath-
eter. The prescribed dose was 15 Gy to a distance of 2 mm
from the surface of the source.
Angiographic analysis. All cineangiograms were analyzed
using CMS-GFT system (Medis, Maastricht, Netherlands)
by an independent angiographic core laboratory (Washing-
ton Hospital Center) that was blinded to the IVUS findings.
With the outer diameter of the contrast-filled catheter used
for calibration, minimum lumen diameter in diastole was
measured from multiple projections, and results from the
“worst” view were recorded. Reference segment diameter
was averaged from user-defined 5-mm-long angiographi-
cally normal segments proximal and distal to the lesion, but
between any major side branches. The diameter stenosis was
calculated as reference diameter minus minimum lumen
diameter divided by reference lumen diameter. Lesion
length was measured as the distance from the proximal
shoulder to the distal shoulder in the projection with the
least amount foreshortening. Angiography was used to
compare the final source placement to the stented segment.
IVUS imaging protocol and analysis. All IVUS studies
were performed after intracoronary administration of
200 g nitroglycerin using a commercially available IVUS
system (Boston Scientific Corporation/SciMed, Maple Grove,
Minnesota). The IVUS catheter was advanced distal to the
lesion and imaging performed retrograde back to the aorto-
ostial junction at an automatic pullback speed at 0.5 mm/s.
We selected the following seven specific cross-sectional
images to represent the anatomic and dose heterogeneity
throughout the length of the treated segment: the sites of
the 1) minimum and 2) maximum distances from the IVUS
catheter to the leading edge of the intima; the sites of the 3)
minimum and 4) maximum distances from the IVUS
catheter to the leading edge of the adventitia (EEM); 5) the
proximal stent edge; 6) the center of the stent; and 7) the
distal stent edge. The IVUS catheter was assumed to
represent the location of the radiation source.
Using planimetry software (TapeMeasure, INDEC Sys-
tems Inc., Capitola, California), EEM cross-sectional area
(CSA), stent CSA and lumen CSA were measured every 1
mm including the seven cross-sections of interest according
to the Standards for the Acquisition, Measurement and
Reporting of Intravascular Ultrasound Studies: A Report of
the American College of Cardiology Task Force on Clinical
Expert Consensus Documents (4). Neointima CSA was
calculated as stent CSA minus lumen CSA within the
stented segment. Using perivascular landmarks and the
known transducer pullback speed, the cross-sections at
postirradiation and follow-up were matched, analyzed and
compared. The change in neointima CSA within the stent
was calculated as follow-up minus postirradiation neointima
CSA. The change in neointima CSA was also averaged over
the length of the stented segment.
In addition, the proximal and distal reference sites and
the minimum lumen CSA site postirradiation and
follow-up were identified and measured. The reference sites
were the most normal looking sections within 5 mm of the
ends of the stents, but before major side branches. Quali-
tative analyses included dissections and incomplete stent
apposition.
Dosimetry analysis. Three-dimensional dosimetric analy-
sis was performed with software developed for intravascular
brachytherapy. We digitized the IVUS images every 1 mm
throughout the stent and reference segments and drew both
luminal and adventitial contours. Intravascular ultrasound
images were imported, and intimal and adventitial contours
were digitally reconstructed. The assumption was made that
the cross-sectional location of the source within the artery
was at the site of the IVUS catheter. The longitudinal
location of the source was determined angiographically by
comparing the radiodense seeds with the stent edges.
Dosimetry calculations were performed by the method
recommended by Task Group-60 (TG-60) of the American
Association of Physicists in Medicine (5), and it was
validated in vitro (6,7). Dose is decomposed into the
product of multiple parameters that describe the source
characteristics. Source information was provided by data
generated from Monte Carlo simulations of a single 192Ir
seed. Gamma, characteristic X-ray, beta, conversion elec-
tron and Auger electron radiations were tracked from the
source and were used to generate pertinent TG-60 dosimet-
ric parameters.
For the seven cross-sections of interest as well as for the
entire stented segment, dose volume histograms (DVH)
were calculated. We assumed that intimal thickness mea-
sured 0.1 mm and adventitial thickness measured 0.5 mm
(8).
Statistics. Statistical analysis was performed using Statview
5.0 (SAS Institute, Cary, North Carolina). Continuous
variables are presented as mean value  1 SD, and categor-
ical variables are presented as frequencies. Continuous
variables were compared using paired Student t test or
simple regression analysis. A p value of 0.05 was consid-
ered significant.
RESULTS
Patient demographics and procedural and angiographic
variables are shown in Tables 1 and 2. The minimum lumen
Abbreviations and Acronyms
CSA  cross-sectional area
DV  dose volume
DVH  dose volume histogram
EEM  external elastic membrane
ISR  in-stent restenosis
IVUS  intravascular ultrasound
TG-60  Task Group-60 of the American Association
of Physicists in Medicine
WRIST  Washington Radiation for In-Stent restenosis
Trial
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diameter decreased and the diameter stenosis increased
slightly, but significantly, from postirradiation to follow-up
(p  0.036 and p  0.006, respectively). Four patients
required target vessel revascularization; however, there were
no deaths, no Q-wave myocardial infarctions and no epi-
sodes of late thrombosis in these 20 patients.
Intravascular ultrasound measurements are shown in
Table 3. There was a decrease in lumen CSA and an
increase in neointima CSA both at the minimum lumen
CSA site and throughout the length of the stent. However,
overall, these changes were modest. The DVHs at the both
intima and adventitia of individual cases are shown in
Figures 1 and 2.
Most of the sites (93%) received a dose of 4 Gy at
adventitia, and all sites received a dose of 4 Gy at intima
(Dv90). To find the best parameter to predict neointimal
regrowth, we compared the increase in neointima CSA to
the Dv5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95 at both the adventitia
and intima at each of the seven preselected cross-sections of
interest. Although there was a weak correlation between
neointimal regrowth and Dv50 at the intima (p 0.003, r
0.32), in general, there were no significant relationships
between neointimal regrowth and dosimetric calculations
(Table 4, Figs. 3 and 4). When the entire stented segment
was evaluated, there was also no significant relationship with
either Dv at intima or Dv at adventitia (Figs. 5 and 6).
Intravascular ultrasound detected three postintervention
distal edge dissections to the media, one dissection to the
media between two stents and five dissections within the
neointima. All were healed at the follow-up. There was no
late stent malapposition at follow-up.
Table 1. Patient Demographics (n  20)
Patient age, (yrs) 57  11
Gender, (M/F) 12/8
Hypertension, (%) 14 (70%)
Diabetes mellitus, (%) 6 (30%)
Hypercholesterolemia, (%) 17 (85%)
Previous in-stent restenosis, (%) 7 (35%)
Previous bypass surgery, (%) 5 (25%)
Previous myocardial infarction, (%) 6 (30%)
Left ventricular ejection fraction, (%) 52.8  8.5
Unstable angina, (%) 17 (85%)
Multivessel disease, (%) 8 (40%)
Table 2. Procedural and Angiographic Variables
LAD/LCX/RCA/LM 9/3/7/1
High speed rotational atherectomy, (%) 15 (75)
New stent, (%) 6 (30%)
Seed length, (19 mm/35 mm/51 mm) 1/10/9
Dwell time, (min) 22.3  4.1
Preintervention
Reference diameter, (mm) 2.7  0.4
Minimum lumen diameter, (mm) 1.0  0.4
Diameter stenosis, (%) 64  14
Lesion length, (mm) 17.2  9.1
Postirradiation
Minimum lumen diameter, (mm) 2.0  0.3
Diameter stenosis, (%) 25  11
Follow-up
Minimum lumen diameter, (mm) 1.8  0.5
Diameter stenosis, (%) 40  18
LAD left anterior descending coronary artery; LCX left circumflex artery; LM
left main artery; RCA  right coronary artery.




Site of the minimum lumen CSA
within the lesion
EEM CSA, (mm2) 15.4  4.2 16.6  4.4 0.2
Stent CSA, (mm2) 7.5  2.5 7.9  2.2 0.4
Lumen CSA, (mm2) 4.8  1.1 4.1  1.6 0.02
Neointima CSA, (mm2) 2.7  2.0 3.8  2.0 0.05
Average over the length of the
lesion
EEM CSA, (mm2) 17.5  4.2 17.5  4.2 0.9
Stent CSA, (mm2) 8.7  2.3 8.7  2.3 0.6
Lumen CSA, (mm2) 6.6  1.6 6.2  1.9 0.07
Neointima CSA, (mm2) 2.1  1.2 2.5  1.2 0.045
Mean of the proximal and distal
reference
EEM CSA, (mm2) 13.5  3.2 13.1  3.5 0.3
Lumen CSA, (mm2) 7.1  1.8 6.1  2.0 0.2
Minimum distance from IVUS
catheter to intimal surface, (mm)
0.6  0.1
Maximum distance from IVUS
catheter to intimal surface, (mm)
2.6  0.4
Minimum distance from IVUS
catheter to adventitial surface,
(mm)
1.2  0.3
Maximum distance from IVUS
catheter to adventitial surface,
(mm)
3.6  0.5
CSA  cross-sectional area; EEM  external elastic membrane; IVUS  intravas-
cular ultrasound.
Figure 1. Individual dose (D) volume (V) histograms at the adventitia for
the entire stent.
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DISCUSSION
Dose heterogeneity and effectiveness. Previous studies in
pig models showed that the effective prescribed dose for
brachytherapy using a gamma source was 3.5 to 14 Gy at
2 mm (9) or 15 to 20 Gy at 1.5 mm (10–12) from the center
of the lumen. Ideally, treatment protocols should be de-
signed to deliver a uniform dose to the target; however, the
source is rarely centered within the lumen, and the lumen
and stent are rarely centered within the artery. This pre-
cludes centering the source within the artery and delivering
a uniform dose to the adventitia.
Human ISR treatment protocols using gamma irradiation
have selected either a fixed prescription (e.g., 15 Gy at 2 mm
from the center of the source [3]) or a calculated and
variable dose prescription (minimum of 8 Gy as long as the
maximum dose is limited to 30 Gy [2,13]). However, in
these ISR protocols, there have been little attempts to
calculate the actual delivered dose and the affect of the
delivered dose on the biologic process—neointimal re-
growth. As shown in Figures 1 and 2, the actual dose ranged
from 4 to 30 Gy at adventitial level and from 8 to 80 Gy at
the intimal level with large dose variability.
In native artery lesions treated with balloon angioplasty
and beta-irradiation, Sabate et al. (14) suggested that 4 Gy
(Dv90 at adventitia) was the threshold to inhibit the neoin-
timal growth (14). However, the dose that inhibits neoin-
timal hyperplasia may be different in normal animal tissue
versus human atherosclerotic tissue and in de novo human
atherosclerotic tissue versus in-stent neointima. Therefore,
we attempted to relate neointimal regrowth and various
DVH values to either the adventitia or intima. In general,
there was no correlation with any specific value of DVH.
However, most (93%) of the cross-sections of interest
received a dose 4 Gy at adventitia. Therefore, we suspect
that using a fixed dose prescription, the overall delivered
dose was enough to prevent the neointimal regrowth even
though there was large dose heterogeneity. However, as
shown in Figures 3 to 6, there were some cross-sections that
received a high dose yet still exhibited a large neointimal
regrowth. Therefore, it is possible that the biological vari-
ability among the patients or along the length of the ISR
site affected neointimal regrowth more than the actual
Figure 3. The relationship between the neointimal regrowth and Dv90 at
adventitia. DV90  dose delivered to at least 90% of the volume.
Figure 4. The relationship between the neointimal regrowth and Dv50
intima. DV50  dose delivered to at least 50% of the volume.
Figure 2. Individual dose (D) volume (V) histograms at the intima for the
entire stent.
Table 4. Correlation Between Neointimal Regrowth and
Calculated Dose
Dependent Variables p r
Dv90 adventitia 0.81 NA
Dv50 adventitia 0.71 NA
Dv10 adventitia 0.30 NA
Dv90 intima 0.012 0.28
Dv50 intima 0.003 0.32
Dv10 intima 0.88 NA
DV  dose volume.
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delivered dose. Finally, gamma-irradiation using an 192Ir
source is considered to be unaffected by the presence of stent
struts and lesion calcium (15).
Target of radiation for ISR. The mechanism of radiation
in preventing recurrent ISR is assumed to be the inactiva-
tion of cells that proliferate, migrate and synthesize matrix
after intervention (16–18). Animal injury models of normal
arteries show that the medial smooth muscle cell and/or
adventitial myofibroblast are the source of the neointima
(19–21). However, when the neointima created by the first
injury is injured again (double-injury model), cell prolifer-
ation occurs in the intima as well as in the media or
adventitia (22,23). Therefore, in treating ISR lesions, the
target may be both the intima as well as the media and
adventitia. For this reason, we evaluated the delivered dose
to both the intimal and the medial-adventitial interface.
This finding may also be part of the explanation for our
inability to relate neointimal recurrence to actual dose
delivery. The intima uniformly received at least 4 Gy.
Clinical implications. We simulated the actual dose dis-
tribution in the clinical setting of gamma-irradiation
brachytherapy using a fixed dose prescription. Although
there was large dose heterogeneity, most of the artery
appeared to receive an acceptable minimum dose. There-
fore, IVUS-guided dose calculations and prescription may
not be necessary. However, we detected cases in which the
intima received very high doses (80 Gy). Caution may be
necessary to avoid adverse effect of radiation (e.g., necrosis
of the vessel) in these patients.
Study limitations. The number of patients was small, and
the recurrence rate was low. Total occlusion cases were
excluded from our analysis. Although we assumed that the
radiation source was located at the same position within the
artery as the IVUS catheter, this might not be correct
because the radiation catheter (5F) was bigger than IVUS
catheter (3.2F). The current analysis assumes the ability to
“align” cross-sections on serial studies.
Conclusions. In patients undergoing brachytherapy using
a gamma emitter and a fixed dose prescription, we were able
to demonstrate a wide variability in actual dose delivered to
the intima and to the adventitia. Nevertheless, there was
little correlation between neointimal reaccumulation and
actual delivered dose, suggesting that a minimum threshold
was achieved in most patients. Other trials, specifically
Scripps Coronary Radiation to Inhibit Proliferation Post
Stenting I and GAMMA I, used a “variable” dose prescrip-
tion (based on IVUS measurements) that resulted in a wide
spectrum of doses received. In the WRIST trial, the dose
was limited to one or two doses based on vessel diameter
only, and this dose prescription appears to be adequate.
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